OR WAIT null SECS
April 09, 2018
The acquisition is expected to accelerate progress towards personalized cancer healthcare.
Roche has acquired a program to develop regenerative therapies for multiple sclerosis.
Under this global collaboration, the companies will develop encapsulated cell therapies for treating Type 1 diabetes.
April 06, 2018
Boehringer Ingelheim and OSE Immunotherapeutics have entered a global immuno-oncology partnership to develop a checkpoint inhibitor for treating advanced solid tumors.
April 05, 2018
Colorcon Inc. and Applied DNA signed a supply agreement granting Colorcon exclusive right to use Applied DNA’s SigNature molecular tags in film coatings for solid oral dosage forms, and non-exclusive rights to use it in inks and colorants for SOD pharmaceuticals.
The companies have created Syna Therapeutics, a joint venture that will develop biosimilars and new molecules.
April 03, 2018
Pfizer transfers CAR-T assets to Allogene Therapeutics under a new alliance to further develop immuno-oncology therapeutics.
March 29, 2018
The acquisition strengthens Celgene’s position in the global cellular immunotherapy space.
The companies will co-develop and co-promote a CAR T cell therapy in the United States.
March 28, 2018
Takeda is considering approaching Shire with a possible offer.